Aiosyn

Name: Aiosyn
Brand: Aiosyn

AI Native

Achieve more perspective through precision pathology

Est 2021|3 Ref Customers

LinkedIn 4K|Web traffic 1K|FTEs 8

01Competitive Landscape

| Aspect | Aiosyn | Paige | PathAI | |---|---|---|---| | Starting Price | Not publicly disclosed; demo/quote-led | Not publicly disclosed; varies by volume/needs | Not publicly disclosed; enterprise/biopharma contracting typical | | Primary Use Cases | EU-focused labs needing IVDR-certified mitosis counting; teams seeking slide QC and kidney quantification modules | Organizations seeking broader clinical AI suites (including some FDA-cleared areas) and enterprise ecosystems | Biopharma and translational research workflows; large-scale pathology AI programs | | Key Strength | Focused, workflow-specific products (QC, mitosis, kidney); EU regulatory positioning for at least one product; platform integrations | Broader suite and established distribution partnerships in some regions | High market visibility and historical funding; broad platform narrative | | Key Weakness | Limited public third-party review coverage; unclear US regulatory status in accessible sources; pricing opacity | Pricing opacity; community concerns about data/business practices have been discussed | Pricing opacity; scope differences between clinical and research offerings can complicate procurement |

Direct competitors and their key differentiators

Aiosyn differentiators
- The vendor has stated that its mitosis-counting product was the first AI solution for that task to be certified under IVDR; procurement teams should verify the scope of the certification and intended use statements in the regulatory documentation.
- A modular slide QC product targeted at common artifact detection and image-quality assessment.
- Kidney-focused quantitative pathology modules for lesion scoring and whole-kidney quantification.
Paige
- Market presence and distribution agreements through pathology marketplace ecosystems and platform partners.
PathAI
- High-profile press coverage and significant historical funding; recent acquisition activity has increased visibility.

Feature comparison: where Aiosyn appears strong vs lagging

Where Aiosyn appears strong
- Focus on operational tasks that can be incorporated into assistive workflows (QC, mitosis detection) rather than claiming broad autonomous diagnostic capability.
- EU regulatory posture (IVDR) for at least one product, which may simplify procurement for that clinical indication within the EU.
Where Aiosyn may lag
- Breadth of algorithm coverage across organ systems compared with larger vendors.
- Volume of publicly available, peer-reviewed validation studies and presence on mainstream review platforms.

Pricing comparison: value proposition vs alternatives

All vendors in this comparison appear to use quote-led pricing in publicly accessible materials; buyers should evaluate contracts based on per-slide or per-case pricing, annual licenses, validation support services, and integration costs.

Customer testimonials comparing products

No direct buyer comparisons between Aiosyn and these competitors were found in the accessible sources.

Market share and adoption trends

No credible public market share figures were identified in the materials reviewed.

01Competitive Landscape

Aspect	Aiosyn	Paige	PathAI
Starting Price	Not publicly disclosed; demo/quote-led	Not publicly disclosed; varies by volume/needs	Not publicly disclosed; enterprise/biopharma contracting typical
Primary Use Cases	EU-focused labs needing IVDR-certified mitosis counting; teams seeking slide QC and kidney quantification modules	Organizations seeking broader clinical AI suites (including some FDA-cleared areas) and enterprise ecosystems	Biopharma and translational research workflows; large-scale pathology AI programs
Key Strength	Focused, workflow-specific products (QC, mitosis, kidney); EU regulatory positioning for at least one product; platform integrations	Broader suite and established distribution partnerships in some regions	High market visibility and historical funding; broad platform narrative
Key Weakness	Limited public third-party review coverage; unclear US regulatory status in accessible sources; pricing opacity	Pricing opacity; community concerns about data/business practices have been discussed	Pricing opacity; scope differences between clinical and research offerings can complicate procurement

Direct competitors and their key differentiators

Aiosyn differentiators
- The vendor has stated that its mitosis-counting product was the first AI solution for that task to be certified under IVDR; procurement teams should verify the scope of the certification and intended use statements in the regulatory documentation.
- A modular slide QC product targeted at common artifact detection and image-quality assessment.
- Kidney-focused quantitative pathology modules for lesion scoring and whole-kidney quantification.
Paige
- Market presence and distribution agreements through pathology marketplace ecosystems and platform partners.
PathAI
- High-profile press coverage and significant historical funding; recent acquisition activity has increased visibility.

Feature comparison: where Aiosyn appears strong vs lagging

Where Aiosyn appears strong
- Focus on operational tasks that can be incorporated into assistive workflows (QC, mitosis detection) rather than claiming broad autonomous diagnostic capability.
- EU regulatory posture (IVDR) for at least one product, which may simplify procurement for that clinical indication within the EU.
Where Aiosyn may lag
- Breadth of algorithm coverage across organ systems compared with larger vendors.
- Volume of publicly available, peer-reviewed validation studies and presence on mainstream review platforms.

Pricing comparison: value proposition vs alternatives

All vendors in this comparison appear to use quote-led pricing in publicly accessible materials; buyers should evaluate contracts based on per-slide or per-case pricing, annual licenses, validation support services, and integration costs.

Customer testimonials comparing products

No direct buyer comparisons between Aiosyn and these competitors were found in the accessible sources.

Market share and adoption trends

No credible public market share figures were identified in the materials reviewed.

Aiosyn

01Competitive Landscape

Direct competitors and their key differentiators

Feature comparison: where Aiosyn appears strong vs lagging

Pricing comparison: value proposition vs alternatives

Customer testimonials comparing products

Market share and adoption trends

02Market Map

01Competitive Landscape

Direct competitors and their key differentiators

Feature comparison: where Aiosyn appears strong vs lagging

Pricing comparison: value proposition vs alternatives

Customer testimonials comparing products

Market share and adoption trends

02Market Map